Earnings Feed
Start Free
LISATA THERAPEUTICS, INC.·4

Jan 13, 4:07 PM ET

Buck Kristen K 4

4 · LISATA THERAPEUTICS, INC. · Filed Jan 13, 2026

Insider Transaction Report

Form 4
Period: 2026-01-09
LISATA THERAPEUTICS, INC.LSTA
Buck Kristen K
EVP, R&D and CMO
Transactions
  • Award

    Common Stock

    [F1][F2]
    2026-01-09+25,000→ 104,794 total
  • Tax Payment

    Common Stock

    [F3][F2]
    2026-01-09$1.97/sh−2,982$5,875→ 101,812 total
  • Tax Payment

    Common Stock

    [F3][F2]
    2026-01-09$1.97/sh−2,982$5,875→ 98,830 total
  • Tax Payment

    Common Stock

    [F3][F2]
    2026-01-09$1.97/sh−3,221$6,345→ 95,609 total
  • Tax Payment

    Common Stock

    [F3][F2]
    2026-01-09$1.97/sh−2,147$4,230→ 93,462 total
  • Award

    Stock Option (Right to Buy)

    [F4]
    2026-01-09+13,000→ 13,000 total
    Exercise: $1.97From: 2026-01-09Exp: 2036-01-09→ Common Stock (13,000 underlying)
Footnotes (4)
  • [F1]Represents 25,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
  • [F2]Includes 38,000 unvested restricted stock.
  • [F3]Shares withheld as payment of a tax liability on vesting of restricted stock.
  • [F4]One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date.
Signature
James Nisco, Attorney-in-Fact for Kristen K. Buck|2026-01-13

Documents

1 file
  • 4
    wk-form4_1768338428.xmlPrimary

    FORM 4